For reducing complement activation due to FH deficiency, drug compounds targeting C3, FB, C5, FP, C3b, C3bB, and C3 convertase are predicted to be efficacious in reducing disease severity (Figure 10). This evidence concerns the gene CFB and hyperinsulinemic hypoglycemia, familial, 4.